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Four-Year Outcome of Aflibercept 
for Neovascular Age-Related 
Macular Degeneration and 
polypoidal choroidal vasculopathy
Keiichi Nishikawa, Akio Oishi  , Masayuki Hata, Masahiro Miyake, sotaro ooto, 
Kenji Yamashiro  , Manabu Miyata  , Hiroshi tamura  , Naoko Ueda-Arakawa, 
Ayako Takahashi, Yu Kawashima & Akitaka Tsujikawa
Intravitreal injections of anti-vascular endothelial growth factor agents such as ranibizumab and 
aflibercept are the first-line treatment for neovascular age-related macular degeneration (AMD). 
However, data about long-term outcome in real-world clinical practice is scarce. We recruited 98 AMD 
patients and investigated four-year visual outcome. During the four years, 25 patients dropped out. The 
survivors received 7.0 ± 0.1 injections during the first year and 8.0 ± 7.4 injections in the following three 
years. The logarithm of minimum angle of resolution (logMAR) at baseline, year one, and year four was 
0.28, 0.14 (P = 0.033), and 0.22 (P = 0.697), respectively. The gain of vision was not different among 
AMD subtypes (typical AMD, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation; 
p = 0.513) Among the investigated factors, the presence of external limiting membrane (ELM), the 
absence of vitreoretinal adhesion, and thicker choroid at baseline were associated with better logMAR 
values at year four (coefficient beta = −0.388, 0.201, and −0.001; P = 7.34 × 10−6; 0.01, and 0.028, 
respectively). In the present study, vision was retained at baseline level after the four-year treatment 
with aflibercept. The status of ELM, vitreoretinal adhesion, and choroidal thickness were predictive 
factors for final vision.
Age-related macular degeneration (AMD) is a leading cause of blindness in developed countries1. Late-stage 
AMD is characterized by geographic atrophy and choroidal neovascularization (CNV). While geographic atro-
phy progresses gradually, CNV causes hemorrhage and exudative changes in the macula, leading to rapid vision 
loss. Indeed, CNV is responsible for more than 80 percent of severe visual loss or legal blindness in patients with 
AMD2.
While there is no established cure for geographic atrophy, CNV can be controlled with vascular endothelial 
growth factor (VEGF) inhibitors. The anti-VEGF agents inhibit CNV growth and fluid leakage, which enable 
visual improvement. However, the treatment has some drawbacks, including a need for frequent intravitreal 
injections; additionally, it is not easy to strictly continue this regimen in clinical practice. Thus, visual gain in 
the first year is generally favorable, but long-term outcome is not as promising. For example, HORIZON and a 
subsequent SEVEN-UP study showed that visual acuity improved during monthly ranibizumab treatment and 
gradually declined thereafter3,4. Another large clinical trial, CATT, reported five-year follow-up data showing 
similar results; after the release from the trial protocol, visual acuity dropped to baseline level5.
While the above-mentioned studies used ranibizumab or bevacizumab, there are other treatment options 
available, such as pegaptanib and aflibercept. Particularly, aflibercept is potentially more effective because it also 
blocks placental growth factor, has a higher affinity for VEGF, and has a longer half-life6. In fact, two-monthly 
injections of aflibercept achieved visual gain identical to monthly ranibizumab7,8. In addition, switching to 
aflibercept in ranibizumab-refractory cases generally shows anatomical improvement9,10. Thus, we predicted that 
aflibercept may yield better long-term visual outcomes than ranibizumab.
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When considering long-term visual outcome, identifying predictive factors for good or poor vision is impor-
tant. Because it is not easy to continue intensive treatment for all patients, identifying those at high-risk and 
investing resources for these patients would improve the visual outcome of the overall cohort.
In the present study, we investigated the four-year visual outcome of aflibercept treatment in patients with 
AMD and explored the factors associated with final vision.
Methods
Study design. Prospective, non-randomized, interventional study.
The study design was approved by the Institutional Review Board of Kyoto University Graduate School of 
Medicine, and all study conduct adhered to the tenets of the Declaration of Helsinki. Each patient gave written 
informed consent for the participation in the study.
Patients and study population. We included treatment-naïve AMD patients between December 2012 and 
December 2013 at Kyoto University Hospital. We had already reported one-year results11, causes of vision loss12, 
and recurrence rate in the second year13. Thus, this is a consecutive study based on the previous research.
The inclusion criteria included an age older than 50 years, axial length less than 26.5 mm, the presence of 
neovascular AMD, and the willingness to participate in the study. The exclusion criteria included any previous 
treatment of CNV and the presence of other retinal diseases such as angioid streaks, vitelliform macular dystro-
phy, and retinal vein or artery occlusion. Those with chronic courses of AMD, indicated by disease history and/or 
massive fibrotic lesions, were also excluded.
Intervention and observation procedure. Each participant underwent three monthly injections fol-
lowed by four two-monthly injections of aflibercept in the first year. The first-year protocol was identical to that 
used in the VIEW I/II studies7,8. After the first year, treatment was continued at the physicians’ discretion. In most 
cases, treatment was administered on an as needed basis (pro re nata, PRN).
As previously reported, we investigated optical coherence tomography images at baseline and at year one—
when the fixed regimen was finished11. Briefly, we measured central retinal thickness, subfoveal choroidal 
Figure 1. The box and whisker plot shows number of aflibercept injections in eyes with neovascular age-
related macular degeneration. (Top) The patients received three monthly injections followed by two-monthly 
treatments in the first year (seven times). Thereafter, additional treatment was administered at the physicians’ 
discretion. The mean number of injections was approximately 2.5 in the following years. Frequency distribution 
of the number of injections is shown in bottom panel. The histogram shows bimodal distribution; some patients 
required almost no injections in the second, third, and fourth years, whereas others required continuous 
injections.
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thickness, and the maximum height of the pigment epithelium detachment. The measurement of CRT and subfo-
veal choroidal thickness was done in horizontal and vertical scans, and the mean value was used for the analysis. 
The presence of external limiting membrane (ELM)/ellipsoid zone (EZ), vitreoretinal adhesions, and reticular 
pseudodrusen was also graded by two of the authors (KN and AO). Any discrepancy in grading was arbitrated 
with a discussion.
We investigated changes in visual acuity as a main outcome measure. Changes in visual acuity in subgroups 
(who had better baseline visual acuity or fewer number of injections) were also investigated. In addition, we per-
formed multivariate regression analysis to identify the baseline characteristics predicting visual outcome.
Statistical analysis. The data are shown as mean and 95% confidence interval unless otherwise specified. 
Statistical analysis was carried out using SPSS version 19 (IBM Japan, Tokyo, Japan). A P-value smaller than 0.05 
was considered significant. Visual acuity was measured with Landolt C charts and was converted to logarithm 
of minimum angle of resolution (logMAR) for the analysis. While we used the results of survivors (who com-
pleted four-year follow up), data that included the dropout patients were also analyzed using a last observation 
carried forward policy for sensitivity analysis. To compare changes from baseline, repeated measures ANOVA 
with post hoc Dunnet correction was applied. Shapiro-Wilk test showed that age followed normal distribution 
and the other investigated factors followed non-normal distribution. Bivariate relationships were examined using 
Pearson’s correlation coefficient for age and using Spearman’s correlation coefficient test for the other continuous 
variables and binary variables. Step-wise multivariate regression analysis was performed with age, CRT, choroidal 
thickness, presence or absence of ELM, EZ, and vitreoretinal adhesion as independent factors and visual acuity 
at year four as a dependent factor.
Results
Among the 98 eyes of 98 patients, 25 (25.5%) dropped out during the follow-up period. Baseline characteristics of 
survivors and dropouts are shown in Supplementary Table. In summary, dropout patients had worse visual acu-
ity and tended to be male. Reasons for dropout included death (unknown reason, one patient), illness (cerebral 
infarction, one patient; non-Hodgkin lymphoma; one patient, traffic accident, one patient), and socioeconomic 
reasons (6 patients). Fifteen patients did not return the hospital for unknown reasons.
The study sample comprised 32 patients with typical AMD, 33 patients with polypoidal choroidal vasculopa-
thy, and 8 patients with retinal angiomatous proliferation. The patients received 7.0 (6.9 to 7.1), 2.5 (1.9 to 3.1), 2.7 
(2.1 to 3.4), and 2.7 (2.2 to 3.3) injections at year one, two, three, and four, respectively (Fig. 1; top). Five patients 
also underwent photodynamic therapy combined with aflibercept. A histogram of the number of injections is 
shown in Fig. 1 (bottom). The result shows bimodal distribution; some patients required no additional treatment 
after one year, while others required continuous injections.
Visual outcome of patients who completed the four-year follow-up is shown in Fig. 2 (top). Visual gain was 
0.14 at year one (0.01 to 0.28, P = 0.033), 0.13 at year two (−0.01 to 0.27, P = 0.069), 0.07 at year three (−0.06 to 
0.21, P = 0.557), and 0.06 at year four (−0.07 to 0.20, P = 0.697). For comparison, visual outcome of all patients—
including those who dropped out—is shown with a dotted line (Fig. 2 top). Survivors had better baseline visual 
acuity, but the gain of vision and subsequent loss of vision thereafter was similar with the dropout-imputed data. 
The prevalence of patients who gained or lost more than 0.3 logMAR is shown in Fig. 2 (bottom). At year one, 
all the patients had gained or maintained vision. In the following years, some patients lost vision, but 94.5% 




Presence of reticular pseudodrusen 0.23 0.055
Clinical factors at baseline
Central retinal thickness (CRT) 0.10 0.400
Maximum height of the pigment epithelium detachment 0.023 0.850
Choroidal thickness −0.24 0.038
Presence of EZ −0.49 1.1 × 10−5
Presence of ELM −0.41 2.7 × 10−4
Presence of vitreous adhesion 0.19 0.110
Clinical factors at year one
Central retinal thickness (CRT) −0.28 0.018
Maximum height of the pigment epithelium detachment 0.23 0.053
Choroidal thickness −0.25 0.033
Presence of EZ −0.50 6.8 × 10−6
Presence of ELM −0.47 2.7 × 10−5
Presence of vitreous adhesion 0.27 0.023
Table 1. Correlation between clinical characteristics and four-year visual outcome in age-related macular 
degeneration patients treated with aflibercept.
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maintained their vision through year four. Gain of vision was 0.07 (0.01 to 0.14) in typical AMD, 0.08 (−0.01 
to 0.16) in PCV, and −0.02 (−0.22 to 0.18) in RAP patients, and there was no difference among the subgroups 
(P = 0.513).
Visual outcome in eyes with baseline logMAR = < 0.2 (36 eyes) and >0.2 (37 eyes) is shown in Fig. 3 (top; 
cut off value of 0.2 is based on median 0.22). The visual course was different between the cases, as expected 
(P = 1.5 × 10−44). While those with worse baseline logMAR gained greater vision in the first year (0.2 vs 0.08, 
P = 8.1 × 10−4), both groups showed similar changes in the subsequent three years. The change in vision from 
year one to year four was 0.09 and 0.06, respectively; this difference was not significant (P = 0.552).
We also investigated visual outcome in eyes that underwent less than 12 treatments (36 eyes) and that those 
that underwent greater than 12 treatments (37 eyes); results are shown in Fig. 3 (bottom; cut off value of 13 
is based on the median). Visual gain in the first year was gradually lost in the following years, but the vision 
remained above the baseline level even at year four in both groups. Two-way ANOVA showed difference in over-
all visual course between the groups (P = 0.004) despite no significant difference at each time point.
Table 1 shows the result of univariate association between clinical factors at baseline, year one, and visual out-
come at year four. The presence of EZ/ELM and choroidal thickness at baseline were associated with final visual 
outcome. Findings at year one showed a similar tendency; the presence of EZ, ELM, and vitreous adhesion, CRT, 
and choroidal thickness at year one showed a significant association. After the stepwise variable selection (Table 2), 
the presence of ELM, vitreous adhesion, and choroidal thickness were found to be significant among baseline factors 
(Coefficient beta = −0.388, P = 7.34 × 10−6; coefficient beta = 0.201, P = 1.31 × 10−2; coefficient beta = −7.66 × 10−4, 
P = 2.77 × 10−2, respectively), while the presence of EZ, ELM, and vitreous adhesion at year one was associated with 
visual outcome (Coefficient beta = −0.163, P = 9.87 × 10−2; coefficient beta = −0.255, P = 2.79 × 10−2; coefficient 
beta = 0.203, P = 1.85 × 10−2, respectively). R2 of the model was 0.351 and 0.350, respectively.
Figure 2. Visual outcome of eyes with neovascular age-related macular degeneration treated with intravitreal 
aflibercept injections. The solid line in the top panel shows the overall result of eyes, which completed the four-
year follow-up. Visual gain in the first year was gradually lost in the following years, but the vision remained 
above the baseline level even at year four. A dotted line shows the data of all patients including those who 
dropped out. Missing data were imputed with a last observation carried forward policy. The visual course in the 
cohort was essentially similar despite the difference of baseline visual acuity, indicating the data of survivors can 
be approximated as a representation of the overall cohort. The bottom graph shows the percentage of patients 
who gained or lost more than three lines of vision. All the patients gained or maintained vision in the first year. 
Although some patients lost vision in the following years, 94.5% maintained their vision even at year four.
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Discussion
The results of the present study showed that the patients with neovascular AMD, who underwent treatment with 
aflibercept, maintained vision for four years. Although the maximum visual gain at year one was not retained, 
94.5% of patients maintained their vision, which would be an acceptable result in clinical practice. Additionally, 
we found that the presence of ELM and vitreous adhesion, at baseline or at year one, can be a predictive factor for 
vision at year four.
The four-year visual outcome in our study was comparable to that of the HORIZON study and the CATT 
follow-up study. The HORIZON study showed that visual gain decreased to two letters, and maintenance of vision 
was achieved in 80.4% of patients at year four. The CATT follow-up study reported a loss of three letters and a 
vision maintenance rate of 87.1% in 5.5 years. The results of the present study showed a four-year visual gain of 
logMAR 0.06, which corresponds to approximately three letters. The present results confirmed that visual gain in 
the first year is gradually lost in the following period in real-world clinical practice.
While the visual outcome was similar to that of previous studies, the total number of injections adminis-
tered in the present study was considerably small. The HORIZON study applied monthly injections during the 
first two years and then administered them PRN in the following two years. The CATT study cohort examined 
groups which had received injections monthly, PRN, or with a switch from monthly to PRN, in the first two years. 
Meanwhile, our study used seven injections in the first year and PRN in the following three years. The mean 
number of injections in the four years was 27.8 in the HORIZON study, 22.6 (13.3 + 9.3) in the PRN arm of the 
CATT trial, and 15.0 in our study. We speculated that a longer half-life of aflibercept would partly contribute to 
the favorable long-term result. Considering that it is not easy to perform continuous anti-VEGF injections in 
actual clinical practice, fewer additional injections, would be beneficial and ideal.
The visual outcome was largely determined by the baseline vision. Those with worse baseline VA gained 
greater vision in the first year but the course in the subsequent three years were similar to that of those with good 
Figure 3. Visual outcome of eyes with neovascular age-related macular degeneration treated with intravitreal 
aflibercept injections. The top graph shows visual outcome in eyes with a baseline logarithm of minimum angle 
of resolution (logMAR) better than 0.2, or not. Those with poor visual acuity at baseline gained more vision in 
the first year. However, both groups showed similar decline of vision in the following year. The visual outcome 
of the group with poor baseline vision did not reach the same level of visual acuity as the group with good 
baseline vision. The bottom graph shows visual outcome in eyes that received more or less than 12 injections. 
Interestingly in this cohort, fewer number of injections was not associated with limited visual gain. Instead, 
those who received a greater number of injections showed slightly inferior outcomes.
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baseline VA. Thus, the gap between the groups were diminished but could never be filled. The result was consist-
ent with previous studies14,15. Patients with good visual acuity tended to gain less vision due to the ceiling effect, 
but they still maintained a higher level of final vision. The result indicates the importance of early detection of the 
disease and prompt treatment. Although the treatment can be used for those with poor baseline visual acuity, it 
is difficult to achieve favorable outcomes once the retina is severely impaired.
Fewer number of injections was not associated with poor visual outcome in the present cohort. Considering 
that AMD is a chronic disease and the anti-VEGF therapy is not a definitive treatment, we expected that cases 
with fewer injections may lose vision due to undertreatment, as reported in a previous study16. However, the 
present result, together with bimodal distribution of required injections, indicated that a certain percentage of 
patients were able to retain vision without intensive treatment once the active phase of the disease was controlled. 
In fact, such remission was also observed with photodynamic therapy17 and ranibizumab18. While proactive treat-
ment, including fixed and treat-and-extend regimens became the current standard, these protocols may lead to 
overtreatment in some patients. Identifying good responders may reduce the treatment burden of patients, physi-
cians, and social economy. Individualized treatment protocols with an observation period may be useful to avoid 
over- and under-treatment19. On the other hand, some cases required more than 30 injections in four years. We 
sometimes applied photodynamic therapy combined with aflibercept (five cases in this cohort) but the result was 
not consistent. Further studies are needed to establish optimal treatment strategy for the low- or non-responders.
Some of the clinical findings at baseline or at year one were associated with visual outcome at year four. 
Specifically, EZ and ELM represented good indicator; they reflected photoreceptor integrity, and the association 
with vision was consistently shown in previous studies20–22. Meanwhile, the association of vitreoretinal adhesion 
was rather unexpected. While the presence of vitreomacular adhesion was associated with neovascular AMD23 
and the negative effect on visual outcome was reported24, the CATT study subanalysis showed no association with 
visual outcome25. Considering the small number of cases with vitreous adhesion (n = 14), the result should be 
interpreted with some reservation. Thick Choroid at baseline was also associated with better visual outcome as 
previously reported26. Difference in choroidal and choriocapillaris blood supply was suggested as a reason for the 
finding26 but the theory is yet to be proven.
The present study has several limitations including relatively small number of patients and considerable drop-
out despite that last observation carried forward analysis suggested that dropout did not bias the result critically. 
Treatment outcome according to CNV subtypes was not significantly different but this can be due to small sample 
size as well. The finding should be confirmed in larger cohort with multi ethnicities. In addition, the treatment 
protocol after the first year was at physicians’ discretion. While the result would reflect real-world outcome, more 
controlled study is needed to confirm scientifically robust evidence of the treatment efficacy.
In conclusion, we showed favorable four-year outcome of aflibercept treatment in patients with neovascular 
AMD. After one year of a fixed regimen protocol, some patients required fewer injections while others needed 
continuous injections. The presence of ELM and the absence of vitreous adhesion were positive indicators of 
vision in the long term. The present result would provide practical information to physicians in this field.
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